Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Steve Chapin
Benralizumab for the Treatment of Severe Eosinophilic Asthma
Prescriber
Pharmacology
Automatic Error Finding in Access-Control Policies
Related publications
The Clinical Profile of Benralizumab in the Management of Severe Eosinophilic Asthma
Therapeutic Advances in Respiratory Disease
Pulmonary
Respiratory Medicine
Pharmacology
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Clinical Pharmacology and Therapeutics
Pharmacology
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma
Annals of Allergy, Asthma and Immunology
Respiratory Medicine
Pulmonary
Allergy
Immunology
Benralizumab, an Add-On Treatment for Severe Eosinophilic Asthma: Evaluation of Exacerbations, Emergency Department Visits, Lung Function, and Oral Corticosteroid Use
Therapeutics and Clinical Risk Management
Daily Patient-Reported Health Status Assessment Improvements With Benralizumab for Patients With Severe, Uncontrolled Eosinophilic Asthma
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Benralizumab: A Unique IL-5 Inhibitor for Severe Asthma
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients With Severe Eosinophilic Asthma
Advances in Therapy
Medicine
Pharmacology
Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
